Dose-adjusted EPOCH-R in MYC Positive DLBCL

• Status: Terminated
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to evaluate the efficacy and toxicity of dose-adjusted EPOCH-R in patients with MYC positive diffuse large B-cell lymphoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fudan University
• Treatments: Cyclophosphamide; Doxorubicin; Etoposide; Prednisone; Rituximab; Vincristine

Criteria

Inclusion Criteria:

• Previously untreated MYC positive diffuse large B-cell lymphoma

• Age range 18-70 years old

• Eastern Cooperative Oncology Group performance status 0-2

• Life expectancy of more than 3 months

• Adequate organ function

Exclusion Criteria:

• Primary or secondary central nervous system involvement

• Previous serious cardiac disease

• History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix

• Pregnant or lactating women

• Serious uncontrolled diseases and intercurrent infection